Point-of-care diagnostic device

- ABREOS BIOSCIENCES, INC.

Latest ABREOS BIOSCIENCES, INC. Patents:

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

FIG. 1 is a top perspective view of the point-of-care diagnostic device, as seen from the top, front, and side;

FIG. 2 is a top plan view thereof;

FIG. 3 is a front elevation view thereof;

FIG. 4 is a right side elevation view thereof;

FIG. 5 is a left side elevation view thereof;

FIG. 6 is a rear elevation view thereof;

FIG. 7 is a bottom plan view thereof; and,

FIG. 8 is a top perspective view of alternative embodiment of the point-of-care diagnostic device, showing the door slid in the open position.

The broken line depiction of a point-of-care device is included for the purpose of illustrating environmental structure and forms no part of the claimed design.

Claims

The ornamental design for a point-of-care diagnostic device, as shown and described.

Referenced Cited
U.S. Patent Documents
5281395 January 25, 1994 Markart et al.
5413764 May 9, 1995 Haar
5567594 October 22, 1996 Calenoff
5885577 March 23, 1999 Alvarez
6146589 November 14, 2000 Chandler
6210901 April 3, 2001 Seidel et al.
7074888 July 11, 2006 Miller et al.
8193002 June 5, 2012 Guo et al.
8507216 August 13, 2013 Kuroda et al.
9250233 February 2, 2016 Kipps et al.
D774205 December 13, 2016 Grace
20030068664 April 10, 2003 Albitar et al.
20050084491 April 21, 2005 Shealy et al.
20050191620 September 1, 2005 McDevitt et al.
20050208587 September 22, 2005 Cardoso et al.
20050272106 December 8, 2005 Moore et al.
20060008920 January 12, 2006 Wong et al.
20060068501 March 30, 2006 Li et al.
20060286379 December 21, 2006 Gao
20100330585 December 30, 2010 Kabri et al.
20110117636 May 19, 2011 Bae et al.
20110136155 June 9, 2011 Mehra et al.
20110320130 December 29, 2011 Valdes et al.
20120220049 August 30, 2012 Bunce et al.
20120225423 September 6, 2012 Schwoebel et al.
20130040401 February 14, 2013 Zin et al.
20130085349 April 4, 2013 Shaanan et al.
20130130404 May 23, 2013 Mehra et al.
20130143246 June 6, 2013 Nelson et al.
20150293086 October 15, 2015 Messmer et al.
20150301031 October 22, 2015 Zin et al.
20160146829 May 26, 2016 Kipps et al.
Foreign Patent Documents
WO-2007022557 March 2007 WO
WO-2009121024 October 2009 WO
WO-2012023053 February 2012 WO
WO-2015160834 October 2015 WO
WO-2016123105 August 2016 WO
Other references
  • Colman et al. Effects of amino acid sequence changes on antibody-antigen interactions. Research in Immunology 145(1):33-36 (1994).
  • Dalakas et al. Effect of Alemtuzumab (Campath 1H) in patients with inclusion-body myositis. Brain 132:1536-1544 (2009).
  • Harlow et al. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 23-26 (1988).
  • Lederman et al. A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4. Mol Immunol 28(11):1171-1181 (1991).
  • U.S. Appl. No. 14/686,578 Office Action dated Oct. 14, 2016.
  • U.S. Appl. No. 14/981,715 Office Action dated Jul. 12, 2016.
  • McDade et al. What a Drop Can Do: Dried Blood Spots As a Minimally Invasive Method for Integrating Biomarkers into Population Based Research. Demography 44(4):899-925 (2007).
  • PCT/US2015/025796 International Preliminary Report on Patentability dated Oct. 27, 2016.
  • U.S. Serial No. 14/981,715 Office Action dated Jan. 19, 2017.
  • U.S. Serial No. 15/185,549 Office Action dated Jan. 6, 2017.
  • Adams et al. Monoclonal antibody therapy of cancer. Nat Biotechnol. 23:1147-1157 (2005).
  • Barenholz et al. A peptide mimetic of the mycobacterial mannosylated lipoarabinomannan: characterization and potential applications. J Med Microbiol 56(pt 5):579-586 (2007).
  • Barnett et al. In-Field Implementation of a Recombinant Factor C Assay for the Detection of Lipopolysaccharide as a Biomarker of Extant Life within Glacial Environments. Biosensors (Basel) 2(1):83-100 (2012).
  • Bazin et al. Rapid visual tests: fast and reliable detection of ochratoxin A. Toxins (Basel) 2(9):2230-2241 (2010).
  • Beum et al. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas. J Immunol Methods 289(1-2)97-109 (2004).
  • Blasco et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immun Methods 325(1-2):127-139 (2007).
  • Breidenbach et al. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432(7019):925-929 (2004).
  • Brissette et al. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel 9:363-369 (2006).
  • Carpino et al. 9-Fluorenylmethoxycarbonyl amino-protecting group. J Org Chem 37(22)3404-3409 (1972).
  • Co-pending U.S. Appl. No. 15/185,549, filed Jun. 17, 2016.
  • Co-pending U.S. Appl. No. 29/568,418, filed Jun. 17, 2016.
  • Degardin et al. Understanding and fighting the medicine counterfeit market. J Pharm Biomed Anal 87:167-175 (2013).
  • Delano et al. Convergent solutions to binding at a protein-protein interface. Science 287(5456):1279-1283 (2000).
  • Ding et al. Endotoxin detection—from limulus amebocyte lysate to recombinant factor C. Subcell Biochem 53:187-208 (2010).
  • FDA—definition of biological product. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.htm (Jul. 2015).
  • Feltrup et al. Development of a fluorescence internal quenching correction factor to correct botulinum neurotoxin type a endopeptidase kinetics using SNAPtide. Anal Chem 84(24):10549-10553 (2012).
  • Fernandez-Salas et al. Botulinum Neurotoxin Serotype a Specific Cell-Based Potency Assay to Replace the Mouse Bioassay. PLoS One 7(11):e49516 (2012).
  • Golden et al. Extended result reading window in lateral flow tests detecting exposure to Onchocerca volvulus: a new technology to improve epidemiological surveillance tools. PLoS One 8(7):e69231 (2013).
  • Hale et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 104(4):948-955 (2004).
  • Hale. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1(3-4):175-187 (1995).
  • Jiang et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2 J Biol Chem 280(6):4656-4662 (2004).
  • Jilani et al. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res 28(12):1255-1262 (2004).
  • Joiner et al. Comparison of Endotoxin Testing Methods for Pharmaceutical Products. Int J Pharm Compd 6:408-409 (2002).
  • Jones et al. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Meth 329(1-2):92-101 (2008).
  • Kosik et al. Studies of enzymatic cleavage of cellulose using polysaccharide analysis by carbohydrate gel electrophoresis (PACE). Methods Enzymol 510:51-67 (2012).
  • Laderman et al. Rapid, sensitive, and specific lateral-flow immunochromatographic point-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. Clin Vaccine Immunol. 15(1):159-163 (2007).
  • Lee et al. Performance improvement of the one-dot lateral flow immunoassay for aflatoxin B1 by using a smartphone-based reading system. Sensors (Basel) 13(4):5109-5116 (2013).
  • Lonza Limulus Amebocyte Lysate (LAL) QCL-1000. Available from: http://bio.lonza.com/uploads/txmwaxmarketingmaterial/Lonza ManualsProductInstructions CL-1000 Product Insert.pdf (2007).
  • Maloney et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6):2188-2195 (1997).
  • Manshouri et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 101(7):2507-2513 (2002).
  • Merrifield. Solid Phase Peptide Synthesis I. J Am Chem Soc 85:2149-2154 (1963).
  • Messmer et al. Specific blocking to improve biopanning in biological samples such as serum and hybridoma supernatants. Biotechniques 30(4):798-802 (2001).
  • Messmer et al. Two human neonatal IgM antibodies encoded by different variable-region genes bind the same linear peptide: evidence for a stereotyped repertoire of epitope recognition. J Immun 162(4):2184-2192 (1999).
  • Montagna et al. A new sensitive enzyme-linked immunosorbent assay (ELISA) for Alemtuzumab determination: development, validation and application. Int J Immunopathol Pharmacol 20(2):363-371 (2007).
  • Mulvaney et al. Incorporating fluorescent dyes and quantum dots into magnetic microbeads for immunoassays. Biotechniques. 36(4):602-609 (2004).
  • Nakamura et al. Lipopolysaccharide-sensitive serine-protease zymogen (factor C) found in Limulus hemocytes. Isolation and characterization. Eur J Biochem 154:511-521 (1986).
  • Nakano et al. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. J Immunol Methods 293:183-189 (2004).
  • Ouimet et al. Comparison of Fluorigenic Peptide Substrates PL50, SNAPtide, and BoTest A/E for BoNT/A Detection and Quantification: Exosite Binding Confers High-Assay Sensitivity. Journal of Biomolecular Screening 18(6):726-735 (2013).
  • PCT/US2009/038674 International Preliminary Report on Patentability dated Sep. 28, 2010.
  • PCT/US2009/038674 International Search Report and Written Opinion dated Dec. 24, 2009.
  • PCT/US2015/025796 International Search Report and Written Opinion dated Aug. 21, 2015.
  • PCT/US2016/14924 International Search Report and Written Opinion dated Apr. 8, 2016.
  • Perosa et al. Identification of an antigenic and immunogenic motif expressed by two 7-merrituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J Immunol 179(11):7967-7974 (2007).
  • Pierce® LAL Chromogenic Endotoxin Quantitation Kit. Available from: https://www.piercenet.com/instructions/2162445.pdf (2013).
  • Poras et al. Detection and Quantification of Botulinum Neurotoxin Type A by a Novel Rapid In Vitro Fluorimetric Assay. Applied and Environmental Microbiology 75(13):4382-4390 (2009).
  • Rebello et al. Pharmacokinetics of CAMPATH-1H: assay development and validation. J Immunol Methods 260(1-2):285-302 (2002).
  • Rohr et al. Immunoassay employing surface-enhanced Raman spectroscopy. Anal Biochem 182(2):388-398 (1989).
  • Sanchez et al. A general process for the development of peptide-based immunoassays for monoclonal antibodies. Cancer Chemother Pharmacol 66(5):919-925 (2010).
  • Shin et al. Combinatorial solid phase peptide synthesis and bioassays. J Biochem Mol Biol 38(5):517-525 (2005).
  • Sosnick et al. Distances between the antigen-binding sites of three murine antibody subclasses measured using neutron and X-ray scattering. Biochemistry 31:1779-1786 (1992).
  • Tan et al. Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors. Clin Cancer Res. 12(21):6517-6522 (2006).
  • Tian et al. Antigen peptide-based immunosensors for rapid detection of antibodies and antigens. Anal Chem 81(13):5218-5225 (2009).
  • Titov et al. Development and optimization of immunoassays for the detection of botulinum toxins. Prikl Biokhim Mikrobiol 48(2):249-256 (2012).
  • Tokunaga et al. Further studies on lipopolysaccharide-sensitive serine protease zymogen (factor C): its isolation from Limulus polyphemus hemocytes and identification as an intracellular zymogen activated by alpha-chymotrypsin, not by trypsin. J Biochem 109:150-157 (1991).
  • U.S. Serial No. 12/934,624 Office Action dated Aug. 22, 2014.
  • U.S. Serial No. 12/934,624 Office Action dated Jan. 8, 2014.
  • U.S. Serial No. 12/934,624 Office Action dated Mar. 27, 2015.
  • Wang et al. Acute intraocular inflammation caused by endotoxin after intravitreal injection of counterfeit bevacizumab in Shanghai, China. Ophthalmology 120(2):355-361 (2013).
  • Williams et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 177:7435-7443 (2006).
Patent History
Patent number: D800912
Type: Grant
Filed: Jun 17, 2016
Date of Patent: Oct 24, 2017
Assignee: ABREOS BIOSCIENCES, INC. (San Diego, CA)
Inventors: Dina Uzri (San Diego, CA), Benedict L. Zin (San Diego, CA), Bradley Todd Messmer (San Diego, CA), Inhoe Kim (San Diego, CA), Gad Shaanan (San Diego, CA), Jessie-Farah Fecteau (Escondido, CA)
Primary Examiner: Wan Laymon
Assistant Examiner: Mark Booker
Application Number: 29/568,417
Classifications
Current U.S. Class: Specimen Handling, Preparation Or Testing (62) (D24/216)